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BACKGROUND
In patients with acquired aplastic anemia, destruction of hematopoietic cells by 
the immune system leads to pancytopenia. Patients have a response to immuno-
suppressive therapy, but myelodysplastic syndromes and acute myeloid leukemia 
develop in about 15% of the patients, usually many months to years after the di-
agnosis of aplastic anemia.
METHODS
We performed next-generation sequencing and array-based karyotyping using 
668 blood samples obtained from 439 patients with aplastic anemia. We analyzed 
serial samples obtained from 82 patients.
RESULTS
Somatic mutations in myeloid cancer candidate genes were present in one third of 
the patients, in a limited number of genes and at low initial variant allele frequency. 
Clonal hematopoiesis was detected in 47% of the patients, most frequently as ac-
quired mutations. The prevalence of the mutations increased with age, and muta-
tions had an age-related signature. DNMT3A-mutated and ASXL1-mutated clones 
tended to increase in size over time; the size of BCOR- and BCORL1-mutated and 
PIGA-mutated clones decreased or remained stable. Mutations in PIGA and BCOR 
and BCORL1 correlated with a better response to immunosuppressive therapy and 
longer and a higher rate of overall and progression-free survival; mutations in a 
subgroup of genes that included DNMT3A and ASXL1 were associated with worse 
outcomes. However, clonal dynamics were highly variable and might not necessarily 
have predicted the response to therapy and long-term survival among individual 
patients.
CONCLUSIONS
Clonal hematopoiesis was prevalent in aplastic anemia. Some mutations were re-
lated to clinical outcomes. A highly biased set of mutations is evidence of Darwin-
ian selection in the failed bone marrow environment. The pattern of somatic 
clones in individual patients over time was variable and frequently unpredictable. 
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A cquired aplastic anemia is caused by immune-mediated destruction of he-matopoietic stem and progenitor cells.1 
CD34+ cells and early progenitors are uniformly 
reduced in aplastic anemia.2 Bone marrow trans-
plantation is curative, and patients may also have 
a response to immunosuppressive therapy.3,4 
With improved survival, the late development of 
myelodysplastic syndromes, acute myeloid leuke-
mia (AML), or both has been noted in about 15% 
of patients and termed “clonal evolution.”5
Although “clonal evolution” historically has 
been used to describe the development of cancer 
in patients with an immune disease, this term is 
a misnomer, since there is evidence of clonal 
hematopoiesis associated with aplastic anemia 
in patients in whom myelodysplastic syndromes 
or AML do not develop. Small numbers of stem-
cell clones were inferred from X-chromosome 
skewing.6 In about half the patients with aplastic 
anemia, there is evidence of a second disease, 
paroxysmal nocturnal hemoglobinuria (PNH),1 
which results from expansion of somatically mu-
tated hematopoietic stem cells. Cytogenetic ab-
normalities,7,8 as well as uniparental disomy of 
the 6p arm (6pUPD),9 have been described in 
aplastic anemia without clinical evidence of myelo-
dysplastic syndromes. However, the origin, impor-
tance, and dynamics over time of clonal hema-
topoiesis in aplastic anemia, and its relationship 
to the development of myelodysplastic syndromes, 
AML, or both, have not been defined. Clonality 
before the development of cancer and thus early 
events in at least one form of leukemogenesis can 
be examined in patients with aplastic anemia.
We used samples obtained from three institu-
tions that specialize in the treatment of patients 
with bone marrow failure to perform targeted 
deep sequencing of genes implicated in myelo-
dysplastic syndromes, AML, or both, with cor-
relation of clonal populations of mutated cells to 
clinical outcomes. In selected cases, we then 
used whole-exome sequencing to characterize 




We enrolled 439 patients with aplastic anemia 
from three centers that specialize in the treat-
ment of patients with bone marrow failure: 256 
patients from the National Institutes of Health 
(NIH), 24 patients from the Cleveland Clinic, 
and 159 patients from Kanazawa University 
(Fig. S1 and Tables S1 and S2 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). Blood, bone marrow, and 
buccal samples were obtained from the patients 
after written informed consent was received ac-
cording to protocols approved by the institutional 
review board at each of the three institutions. 
Germline DNA was available from CD3+ T cells 
obtained from patients from the NIH and Cleve-
land Clinic and from buccal smears obtained 
from 22 patients from Kanazawa University. 
Serially obtained specimens were available from 
82 patients. In total, 668 blood samples were 
analyzed. The criteria for diagnosis, disease se-
verity, response to immunosuppressive therapy, 
and relapse have been described previously.3 For 
the NIH cohort, per protocol, clonal evolution to 
myelodysplastic syndromes or AML was defined 
as identification of a chromosomal abnormality 
by means of metaphase karyotyping, the presence 
of frank morphologic dysplasia, or an increase 
in the level of CD34+ cells detected on examina-
tion of the bone marrow.
The last two authors designed the study, and 
five of the authors gathered the data. The last 
two authors vouch for the integrity and com-
pleteness of the data and analyses and the fidel-
ity of the study to the protocol. Sequencing and 
genotype data from the study have been deposited 
in the European Genome-Phenome Archive under 
accession number EGAS00001001153.
DNA Sequencing and Single-Nucleotide 
Polymorphism Array
Methods of whole-exome and targeted sequenc-
ing and single-nucleotide polymorphism (SNP)–
array karyotyping were reported previously10-12 
(see the Supplementary Appendix). The panel of 
106 genes for targeted sequencing included most 
of the genes known to be mutated in myeloid 
cancers, as well as PIGA (Table S3 in the Supple-
mentary Appendix). The mean depth for target-
ed sequencing was 1248×, and the mean depth 
for whole-exome sequencing was 112× (Table S4 
in the Supplementary Appendix). Somatic muta-
tions were detected with the use of a frequency 
threshold of 0.07 (whole-exome sequencing) or 
0.02 (targeted sequencing) for variant allele fre-
quency and were individually validated with the 
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use of deep sequencing of polymerase-chain-
reaction–amplified targets (with assessment of 
specific variant reads in healthy controls when-
ever possible).
Statistical Analysis
Random survival forests13 and the penalized like-
lihood approach to variable selection14 were used 
to identify subsets of mutated genes that corre-
lated with clinical outcomes. Multiple logistic-
regression and Cox proportional-hazards mod-
els were used to evaluate mutations in gene sets 
and competing risk factors (see the Supplemen-
tary Appendix). Full details of the statistical 
analysis are provided in the Methods section in 
the Supplementary Appendix.
R esult s
Targeted Sequencing and SNP Array 
Karyotyping
Targeted sequencing of a panel of genes that are 
recurrently mutated in myeloid cancers was per-
formed with the use of blood obtained from all 
439 patients who had aplastic anemia. Overall, 
249 somatic mutations were detected among 156 
patients (36%); 56 of these 156 patients (36%) 
had multiple mutations (range, 1 to 7 mutations) 
(Fig. S2A in the Supplementary Appendix). The 
most frequently mutated genes were BCOR and 
BCORL1 (in 9.3% of the patients), PIGA (in 7.5%), 
DNMT3A (in 8.4%), and ASXL1 (in 6.2%), which 
together accounted for 77% of all mutation-
positive patients. The overall mutation rate and 
the predominant mutations were similar in the 
U.S. and Japanese cohorts (Fig. 1, and Fig. S2A 
and Table S5 in the Supplementary Appendix).
Except in the case of the PIGA and BCOR and 
BCORL1 mutations, both the presence and the 
number of mutations per patient positively corre-
lated with age (P<0.001 for both comparisons) 
(Fig. 1B). In 6 patients, multilineage involvement 
of mutations was confirmed by means of ampli-
con sequencing of genomic DNA from flow-
sorted fractions of hematopoietic stem cells, com-
mon myeloid progenitors, and myeloid erythroid 
progenitors, although, as expected, the numbers 
of cells in these fractions were reduced (Fig. S3 
and Table S6 in the Supplementary Appendix).
Samples in the NIH cohort were obtained 
6 months after the initiation of immunosuppres-
sive therapy. In that cohort, diagnostic samples 
were available for 45 patients; 79 mutations were 
found in these patients. Amplicon sequencing 
confirmed that the majority of these mutations 
(58 of 79) were present at diagnosis at a variant 
allele frequency that was much lower than that 
at 6 months after treatment (P<0.001) (Fig. 1C). 
There was no significant difference in the rela-
tive number of mutations in each gene at diagno-
sis and at 6 months after treatment (Fig. S2B in 
the Supplementary Appendix); this indicates that 
these mutations were present before treatment.
As has been reported previously,9 the most 
prevalent abnormality in SNP array karyotyping 
was 6pUPD, which was present in 13% of the 
patients in each cohort (Fig. S4 in the Supple-
mentary Appendix). Copy-number variations were 
detected in 18 of 417 samples analyzed and in-
cluded −7 (in 7 patients), del(13q) (in 2 patients), 
and others (in 10 patients) (Fig. S4 in the Supple-
mentary Appendix). With the use of both plat-
forms, clonal hematopoiesis was identified in 
47% of patients.
Candidate-gene mutations in aplastic anemia 
recapitulated those in myelodysplastic syndromes, 
AML, or both with respect to positional distribu-
tion and a strong bias toward nonsense, frame-
shift, and splice-site changes (Fig. S5A in the 
Supplementary Appendix).15-19 However, the mean 
allelic burden of mutations in aplastic anemia 
was substantially lower than that in myelodys-
plastic syndromes (9.3% vs. 30.4%) (Fig. S5B and 
S5C in the Supplementary Appendix).20 Although 
DNMT3A and ASXL1 mutations were frequent both 
in aplastic anemia and in myelodysplastic syn-
dromes and AML, we observed overrepresenta-
tion of PIGA and BCOR and BCORL1 mutations 
and underrepresentation of mutations in TET2, 
splicing-factor genes, JAK2, RUNX1, and TP53 in 
aplastic anemia, as compared with myelodysplas-
tic syndromes; this suggested discrete mecha-
nisms of clonal selections in aplastic anemia.
Some patients carried multiple mutations in 
the same genes, including PIGA, BCOR, DNMT3A, 
ASXL1, RUNX1, and ZRSR2. In 11 male patients, 
there were 22 mutations in X-chromosome genes; 
therefore, they were probably within indepen-
dent subclones (Fig. S5D in the Supplementary 
Appendix). This was explicitly observed with the 
use of single-colony sequencing in 2 patients 
carrying 2 BCOR mutations (Patient NIH076) and 
3 PIGA mutations (Patient NIH207) (Table S7 in 
the Supplementary Appendix).
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Clinical Correlations
The effect of gene mutations on clinical outcomes 
was assessed first in the NIH cohort, in which 
samples were uniformly obtained 6 months after 
treatment and all patients had severe aplastic 
anemia. There was no apparent relationship be-
tween the presence of mutations and the re-
sponse to immunosuppressive therapy (P = 0.28) 
(Fig. S6A in the Supplementary Appendix), but 
when the mutated genes were assessed individu-
ally, BCOR and BCORL1 mutations favored a good 
response to immunosuppressive therapy (P = 0.013) 
(Fig. S6B in the Supplementary Appendix). Logis-
tic regression with the use of multiple variables 
that were previously reported to correlate with a 
response to treatment at 6 months21 showed 
that BCOR and BCORL1 remained independently 
associated with a response (Table S8 in the 
Supplementary Appendix).
Similarly, there was no significant difference 
in overall survival and progression-free survival 
(evolution to myelodysplastic syndromes, AML, 
or both) between all patients with somatic mu-
tations and those without mutations (Fig. S7A 
in the Supplementary Appendix). We next used 
machine-learning methods to assess associa-
tions between gene mutations and clinical out-
comes. Both random survival forests and algo-
rithms for the penalized likelihood approach to 
variable selection identified patients with better 
responses to immunosuppressive therapy (those 
with PIGA and BCOR and BCORL1) and patients with 
worse responses (those with ASXL1, DNMT3A, 
TP53, RUNX1, JAK2, JAK3, and CSMD1) than the 
responses in patients without these mutations 
(“unmutated” group) (Fig. 2A). We also identified 
patients with better overall survival (those with 
PIGA and BCOR and BCORL1) and patients with 
worse overall survival (those with ASXL1, DNMT3A, 
TP53, RUNX1, and CSMD1) than overall survival in 
the unmutated group (Fig. 2B), and patients with 
better progression-free survival (those with PIGA 
and BCOR and BCORL1) and patients with worse 
progression-free survival (those with ASXL1, 
DNMT3A, RUNX1, JAK2, and JAK3) than progres-
sion-free survival in the unmutated group 
(Fig. 2C). Assessment of the Japanese cohort 
with the use of the same gene set confirmed the 
relationship of ASXL1, DNMT3A, TP53, RUNX1, and 
CSMD1 to lower overall survival among patients 
with severe aplastic anemia (Fig. S7B in the 
Supplementary Appendix). Patients with “mixed” 
mutations — both “favorable” (PIGA or BCOR and 
BCORL1) and any other mutated gene — were 
excluded from these analyses, but stratification 
in models was enhanced if these patients were 
grouped with the favorable gene set for response 
to therapy and overall survival (see below) and 
with unfavorable genes for progression-free sur-
vival (data not shown).
Since age correlated with the presence of mu-
tations and is a known risk factor for poor over-
all survival among patients with aplastic ane-
mia,22 a Cox proportional-hazards model was 
used to determine whether mutations were in-
dependent risk factors (Table 1). “Favorable” 
somatic mutations were associated with good 
overall survival (model 1), and “unfavorable” 
mutations, older age, male sex, and a lower 
initial reticulocyte count were associated with 
poor overall survival (model 2). Overall survival 
among younger patients was particularly influ-
enced by the presence of unfavorable mutations 
(Fig. 2D, and Fig. S8 in the Supplementary Ap-
pendix).
Chronology of Clonal Architecture in 
Aplastic Anemia
We used whole-exome sequencing to define 
clonal hematopoiesis over time. Comprehensive 
detection of coding-sequence mutations was 
achieved in 135 samples obtained from 52 pa-
tients, including serially obtained samples from 
28 patients (Table S9 in the Supplementary Ap-
pendix). Sample selection was biased toward 
patients with known mutations in targeted 
genes, since the analysis was intended to depict 
clonal architecture preceding clinical evolution 
Figure 1 (facing page). Somatic Mutations Identified  
by Means of Targeted Sequencing.
Panel A shows the frequency of mutated genes and 
type of mutations in each gene identified in the U.S. 
cohorts (from the National Institutes of Health [NIH] 
and the Cleveland Clinic) and the Japanese cohort 
(from Kanazawa University). Panel B shows the fre-
quency (top) and mean number (bottom) of mutations 
in various age groups for indicated sets of mutations 
with corresponding regression lines. Panel C shows 
the variant allele frequency of mutations detected at 
the time of diagnosis and 6 months after immunosup-
pressive therapy (IST) in the NIH cohort. Red lines in-
dicate mutations with a higher allele frequency (or the 
same allele frequency) at diagnosis than at 6 months 
after IST; gray lines indicate the rest of the mutations.
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Figure 2. Clinical Correlations with Somatic Mutations.
Gene-set enrichment analysis with the use of algorithms for a penalized likelihood approach to variable selection was used to identify 
sets of genes that were associated with a good or poor response to immunosuppressive therapy (Panel A), overall survival (Panel B), 
and progression-free survival (Panel C) in the NIH cohort. Panel A shows an inferior response to immunosuppressive therapy in a group 
of patients with “unfavorable” mutations (DNMT3A, ASXL1, TP53, RUNX1, JAK2, JAK3, or CSMD1) and a superior response in patients 
with “favorable” mutations (PIGA or BCOR and BCORL1) as compared with patients in an “unmutated” group (P = 0.03 by the chi-square 
test). The width of each column represents the number of patients in each group. CR denotes complete response, NR nonresponse, and 
PR partial response. In Panel B, Kaplan–Meier curves for overall survival are shown for three groups: patients with favorable mutations 
in PIGA or BCOR and BCORL1, patients in the unmutated group, and patients with unfavorable mutations in DNMT3A, ASXL1, TP53, 
RUNX1, or CSMD1. In Panel C, Kaplan–Meier curves for progression-free survival among patients with favorable mutations in PIGA, 
BCOR or BCORL1, patients in the unmutated group, and patients with unfavorable DNMT3A, ASXL1, RUNX1, JAK2, or JAK3 mutations 
are shown. In Panel D, Kaplan–Meier curves for overall survival among patients younger than 60 years of age are shown for three groups: 
patients with favorable mutations in PIGA or BCOR and BCORL1, patients in the unmutated group, and patients with unfavorable muta-
tions in DNMT3A, ASXL1, TP53, RUNX1, or CSMD1. Log-rank tests were used for statistical comparisons among the groups. The un-
mutated group included patients with other candidate-gene mutations that did not cluster in gene-set enrichment analysis with either 
favorable or unfavorable groups. Results were similar when patients in the unmutated group (no candidate-gene mutations detected) 
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to myelodysplastic syndromes, AML, or both. In 
total, 95 somatic-mutation events in 25 of 52 
patients (48%) were detected and validated by 
means of amplicon sequencing. Acquired muta-
tions in exomes of genes of unknown signifi-
cance defined hematopoietic-cell clones in an-
other 5 of the 52 patients who were evaluated 
(Fig. S9A in the Supplementary Appendix).
When all platforms were combined, clonal 
hematopoiesis was detected in 85% of the 52 
samples (Table S10 in the Supplementary Ap-
pendix). The mean number of nonsynonymous 
mutations per sample was 1.21 (when synony-
mous mutations were included, the total mean 
number of mutations was 1.83) (Fig. S9A in the 
Supplementary Appendix), and the mean num-
ber of nonsynonymous mutations increased sig-
nificantly with age (Fig. S9B in the Supplemen-
tary Appendix). Mutations were prominently 
biased toward an age-related cytosine-to-thy-
mine (C→T) transition at CpG dinucleotides; this 
was true as well of mutations detected by means 
of targeted sequencing (Fig. S9C in the Supple-
mentary Appendix). Transitions also accumulat-
ed in healthy older adults (Fig. S10 in the Supple-
mentary Appendix).23-25 With the exception of 
genes included in targeted sequencing, only four 
very large genes (ITGA1, HDLBP, AKAP9, and 
MUC16) harbored recurrent mutations. The pres-
ence of multiple subclones, inferred from signifi-
cantly different variant allele frequencies of dis-
tinct mutations in targeted sequencing at 6 months 
after treatment, was confirmed by means of 
whole-exome sequencing that revealed addition-
al new mutations.
A more detailed analysis of clonal evolution 
was obtained by the sequencing of serial samples 
from 35 patients that spanned years. In most 
patients, clonal hematopoiesis originated from a 
minor clone that was already present at the time 
of diagnosis. However, the subsequent temporal 
course of these clones was highly variable. In 
some cases, clones containing mutations were 
stable over a period of years (median, 5 years; 
Variable Model 1 Model 2
Hazard Ratio for Death  
(95% CI) P Value
Hazard Ratio for Death 
(95% CI) P Value
Age >60 yr 2.72 (1.51–4.90) <0.001 2.50 (1.41–4.43) 0.002
Male sex 2.30 (1.27–4.17) 0.006 2.27 (1.25–4.10) 0.007
Somatic-mutation category
Favorable 0.27 (0.09–0.78) 0.016 — —
Unmutated 0.56 (0.29–1.09) 0.09 — —
Mixed 0.23 (0.05–1.05) 0.06 — —
Combined — — 0.48 (0.25–0.91) 0.03
Blood counts at diagnosis
Reticulocytes 0.43 (0.22–0.84) 0.014 0.47 (0.25–0.88) 0.02
Neutrophils 0.67 (0.26–1.72) 0.42 0.67 (0.26–1.75) 0.41
Lymphocytes 1.63 (0.89–2.97) 0.11 1.46 (0.83–2.60) 0.19
Platelets 1.18 (0.57–2.46) 0.66 1.34 (0.65–2.79) 0.43
*  A multivariate Cox proportional-hazards model was used to assess risk factors. Reference (baseline) groups for cate-
gorical variables were as follows: an age of 60 years or younger, female sex, and “unfavorable” mutations. Blood counts 
at the time of diagnosis were treated as continuous variables after log10 transformation. The P value for each variable 
was obtained with the use of a likelihood-ratio test. In model 1, each individual gene set (“favorable,” “unmutated,” 
and “mixed” mutations) was compared separately with the unfavorable gene set as a reference. In model 2, all other 
gene sets were combined for comparison with the unfavorable gene set. Categories of somatic mutations were derived 
with the use of algorithms for a penalized likelihood approach to variable selection for favorable mutations (PIGA and 
BCOR and BCORL1), unfavorable mutations (ASXL1, DNMT3A, TP53, RUNX1, and CSMD1), and unmutated cases 
(none of these mutations or no mutations); 13 patients had mixed mutations.
Table 1. Risk Factors Associated with Poor Overall Survival.*
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range, 2 to 10), generally with persistent cytope-
nias (Fig. S11 in the Supplementary Appendix). 
In others (Figs. 3A, 3B, and 3C, and Fig. S12 in 
the Supplementary Appendix), a large hemato-
poietic stem-cell clone gradually dominated the 
blood compartment, and new subclones were 
observed preceding the development of myelo-
dysplastic syndromes, AML, or both (Fig. S13 in 
the Supplementary Appendix).
In Patient NIH075 from the NIH cohort, in 
whom mutations were fully assessed over the 
course of 12 years, clonal hematopoiesis was 
shaped by multiple rounds of acquisition of new 
mutations and clonal selection with progression 
of thrombocytopenia after an initial response to 
immunosuppressive therapy (Fig. 3B). The origi-
nal clone, which was characterized by an OR51A4 
mutation, gave rise to several independent clones 
carrying ASXL1, EHD2, or coexisting TET2 and 
BCOR mutations (Table S7 in the Supplementary 
Appendix), some of which appeared and disap-
peared, with the ultimate emergence of new 
subclones within the compartment carrying the 
ASXL1 mutation (Fig. 3D). Patient NIH075 had 
persistent thrombocytopenia, which was respon-
sive to cyclosporine. Serial bone marrow sam-
ples showed decreased megakaryocytes, but there 
was no apparent dysplasia, nor were there in-
creased blasts or cytogenetic abnormalities. In 
other patients (Patients NIH044 and NIH169), a 
dominant clone was compatible with normal or 
near-normal blood counts. Nevertheless, clones 
with DNMT3A, ASXL1, RUNX1, or U2AF1 mutations 
tended to continue to become larger over time, 
whereas the size of clones with PIGA and BCOR 
and BCORL1 mutations was stable or decreased 
(Fig. 4, and Fig. S14 in the Supplementary Ap-
pendix).
Discussion
Through targeted deep-sequencing, SNP array 
karyotyping, and whole-exome sequencing, we 
delineated a broad registry of genetic alterations 
in aplastic anemia and described their dynamics 
over long clinical courses. The combined results 
of all the assays that we used showed that about 
half the patients with aplastic anemia in the 
study had evidence of expanded hematopoietic 
cell clones, and about one third had acquired 
mutations in candidate genes for myelodysplas-
tic syndromes, AML, or both. These results have 
implications for bone marrow failure, for early 
events in leukemogenesis, and for normal aging.
Clonal hematopoiesis in aplastic anemia was 
manifested most frequently as somatic mutations 
in a very few common driver genes (DNMT3A, 
ASXL1, and BCOR and BCORL1) for myelodysplastic 
syndromes, AML, or both. Our findings are con-
sistent with those of recent studies26-28 in which 
candidate-gene targeted sequencing also showed 
recurrent mutations in a similar spectrum of 
genes. In the first study, mutations were de-
scribed as rare, but 2 of 39 patients had muta-
tions with low variant allele frequency in ASXL1 and 
1 had a DNMT3A mutation.26 In two studies27,28 in 
which samples were obtained at various times 
after diagnosis, mutations in ASXL1, DNMT3A, and 
BCOR were prevalent in 19% of patients seen at 
King’s College Hospital, London (samples were 
obtained relatively late after diagnosis) and were 
rare in a German study in which myelodysplastic 
syndrome mutations were detected in 2 of 38 
patients (mutations with low variant allele fre-
quency were excluded).
As compared with these recent studies, our 
data set was larger and involved a more consistent 
collection of samples at specified time points 
over the course of disease. Our analysis by means 
of whole-exome and deep sequencing, the con-
firmation of putative mutations with the use of 
multiple methods, and the consistency of find-
ings among three cohorts define a spectrum of 
genomic abnormalities in aplastic anemia. Re-
Figure 3 (facing page). Temporal Profile of Mutations 
Detected by Means of Whole-Exome Sequencing.
Panels A through C show the results of a representative 
secular analysis of somatic mutations and their relation-
ship to peripheral-blood counts and response to immu-
nosuppressive therapy. White-cell counts (top) and the 
variant allele frequency of mutations identified by means 
of whole-exome sequencing (bottom) are shown. The 
treatment received is shown at the bottom of each panel. 
CR denotes complete response, CsA cyclosporine, 
hATG horse antithymocyte globulin, NR nonresponse, 
PR partial response, and rATG rabbit antithymocyte 
globulin. Asterisks indicate the samples that were not 
used in whole-exome sequencing. Panel D shows the 
chronologic history of clonal evolution from the onset 
of disease to the last follow-up in Patient NIH075. Each 
mutated gene is depicted in the representative cells. 
The vertical axis indicates the absolute volume of the 
clones. Representative mutations in each clone are 
also shown. HSC denotes hematopoietic stem cell.
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sults from recent studies as well as our study 
concerning the specific genes mutated and their 
low variant allele frequency in aplastic anemia 
raise important questions about disease classifi-
cation, pathophysiology, and clinical practice.
First, despite a substantial overlap in recur-
rently mutated genes between aplastic anemia 
and myelodysplastic syndromes, these mutations 
were generally detected in small subpopulations, 
mostly at less than 10% variant allele frequen-
Figure 4. Temporal Profile of Common Mutations in the NIH Cohort.
The variant allele frequencies of mutations in commonly affected genes such as DNMT3A (Panel A), ASXL1 (Panel B), BCOR and BCORL1 
(Panel C), and PIGA (Panel D) are plotted for all relevant mutations. Each line indicates the time course of variant allele frequencies for 
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cies, and at least 6 months after treatment; usu-
ally years are required before clones achieve 
dominance. Various sets of mutations show dis-
tinct behavior and clinical effect; BCOR-mutant 
and BCORL1-mutant clones and PIGA-mutant 
clones tended to disappear or remain small, were 
associated with a better response to immuno-
suppressive therapy, and predicted favorable out-
comes. In contrast, clones carrying mutations in 
DNMT3A, ASXL1, and a few other genes were more 
likely to increase in size over time, and these 
mutations (dominated by DNMT3A and ASXL1) as 
a group were associated with a poorer response 
to immunosuppressive therapy, inferior overall 
survival, and progression to myelodysplastic syn-
dromes, AML, or both. Thus, in these cases, 
clonal hematopoiesis may represent the earliest 
stages of leukemogenesis visualized by deep se-
quencing before evident neoplastic expansion. 
Preleukemic clones in primary AML also fre-
quently harbor DNMT3A mutations.29,30 The pres-
ence of monosomy 7 at 6 months after treatment 
also predicted poor overall survival and progres-
sion to myelodysplastic syndromes (Fig. S15 in 
the Supplementary Appendix).
Second, our results show parallels between 
bone marrow failure and normal aging of the 
hematopoietic compartment. The characteristic 
mutation signature and correlation of mutations 
with patient age suggested age-related, sponta-
neous conversion of methylated cytosine (mC) to 
thymidine at mCpG sites31 as a major source of 
nucleotide alterations in aplastic anemia.32 Simi-
lar C-to-T conversion mutations accumulate in 
hematopoietic progenitors in healthy persons 
(Fig. S11 in the Supplementary Appendix).23-25 
Age-related clonal hematopoiesis, as detected by 
means of SNP array karyotyping33,34 and exome 
sequencing,24,25,35 was identified in 1 to 3% of 
patients with nonhematologic cancers and in 
healthy persons, showed a strong correlation 
with age, and was associated with a higher risk 
of the development of subsequent hematologic 
cancers.24,25,33-36 Mutations generally appeared at 
a low variant allele frequency, were predominantly 
C-to-T conversions, and involved common muta-
tional targets in myeloid cancers,24,25,33-36 which 
suggests that the origin and clonal selection of 
these mutations are similar to those in aplastic 
anemia. The incidence of clonal hematopoiesis 
was much higher among patients with aplastic 
anemia, and BCOR and BCORL1 and PIGA muta-
tions were overrepresented, whereas TET2 and 
JAK2 were infrequently mutated, which suggests 
that distinct mechanisms of clonal selection 
operate in the aplastic bone marrow environ-
ment. Nevertheless, acquisition of specific muta-
tions (detected by means of candidate-gene se-
quencing), an increased mutational burden in 
dominant clones (detected by means of whole-
exome sequencing), and accelerated telomere 
attrition preceding development of myelodys-
plastic syndromes, AML, or both37 suggest a 
common mechanism that links genome aging in 
bone marrow failure with that in the healthy 
elderly.
Third, specific mutations probably have func-
tional relevance,38,39 but the exact mechanism of 
selection of mutated cells in aplastic anemia is 
unclear. Cells containing DNMT3A or ASXL1 mu-
tations may preferentially self-renew rather than 
differentiate in response to extrinsic signals that 
are especially abundant in bone marrow failure. 
We speculate that clones containing mutated 
genes that are present in aging bone marrow are 
selected in bone marrow failure; the lower preva-
lence of such clones in healthy elderly persons as 
compared with persons with aplastic anemia 
may be due to the insensitivity of deep sequenc-
ing for detecting very small populations of ab-
normal cells (since flow cytometry is far more 
sensitive than PIGA sequencing for the detection 
of small PNH clones). That clones containing 
DNMT3A or ASXL1 mutations might initiate a 
pathogenic immune response would seem un-
likely given the inverse correlation of their pres-
ence with response to immunosuppressive ther-
apy. In contrast, the striking overrepresentation of 
BCOR and BCORL1 and PIGA mutations as well as 
frequent 6pUPD involving specific HLA classes9 
suggest a mechanism of protection of mutated 
cells from immune-mediated destruction by path-
o genic T cells.40,41 Stratification in our models 
was enhanced if patients who had a mixed pat-
tern of both favorable and unfavorable muta-
tions were grouped in the favorable gene set for 
early outcomes (response to therapy and overall 
survival) and with unfavorable genes for later 
progression-free survival — consistent with the 
dynamics of their clonal behavior over time and 
presumed functionality.
Finally, despite the association of particular 
gene mutations observed early in the course of 
disease with the response to therapy and sur-
vival, it should be underscored that the complex 
dynamics of clonal hematopoiesis are highly vari-
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able and not necessarily determinative. Mono-
somy 7 can develop in the absence of candidate-
gene mutations in patients with aplastic anemia,37 
and virtually monoclonal hematopoiesis, includ-
ing multiple unfavorable mutations, can be pres-
ent in patients who have a response to immuno-
suppressive therapy, maintain good blood counts, 
and have prolonged survival. Close monitoring 
of clonal hematopoiesis by means of both deep 
sequencing and SNP array karyotyping will need 
to be combined with clinical evaluation to esti-
mate prognosis and to guide treatment of pa-
tients with aplastic anemia.
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